Form 4: Ligand Pharmaceuticals Director Exercises Stock Options
SEC Form 4 Filing
Jason Aryeh, a director at Ligand Pharmaceuticals, exercised stock options on March 5, 2024, acquiring 2,893 shares at $39.35.
Summary
- On March 5, 2024, Jason Aryeh, a director of Ligand Pharmaceuticals, exercised non-qualified stock options.
- This transaction involved the acquisition of 2,893 shares of common stock at a price of $39.35 per share.
- Following the transaction, Mr. Aryeh directly owns 74,422 shares and indirectly owns 51,594 shares through certain funds and 5,025 shares by Trust.
- The options were previously reported as a grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral report of a transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 04/24/2015 | Options vested in full |
| 03/05/2024 | Date of transaction: Stock options exercised |
| 03/06/2024 | Date of Form 4 filing |
| 06/04/2024 | Expiration date of the Non-Qualified Stock Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.